A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION
The purpose of the study is to compare the good and bad effects of atezolizumab plus bevacizumab, versus not receiving any treatment.
The study includes participants who have had surgery to remove their liver cancer and are at high risk of their cancer returning.
- 18 years or older
- Have had curative resection or ablation
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Evidence of residual, recurrent, or metastatic disease at randomization
18 - 100
Healthy Volunteers Needed
Duration of Participation
1 year of study drug. After your final dose, your investigator will follow up with you about every 3 months for as long as you agree to it.
Knight Clinical Trials Information Line
F. Hoffmann-La Roche Ltd